Supply chains felt the full force of the COVID-19 pandemic, leading the industry to rapidly adopt new protocols. Additional forces have also exposed the supply chain to even more complex issues such as increased lead times and sustainability. This eBook examines the lessons learned from the pandemic that have become standard among biomanufacturers and how rising macroeconomic threats such as inflation and climate change continue to force supply chains to evolve.
Jim Marshall, associate director of materials management at Alnylam, and Imara Charles, vice president of strategic supplier partnerships and third-party risk management at Bristol Myers Squibb, address the value of manufacturers working strategically with suppliers and why new approaches to partnerships are needed.
Supply-chain security remains an issue throughout the industry. Dan Johnson, senior director of digital supply chain enablement at Thermo Fisher Scientific, and consultant John Cannon of MKA Insights touch on the challenges the supply chain is still confronting as the result of COVID-19, including the danger of single sourcing materials. Also discussed are solutions to dealing with these supply-chain challenges, including incorporating a robust risk management process and digitizing the supply chain.
Finally, learn how the cell and gene therapy (CGT) sector is tackling its own supply-chain concerns. Leading experts from GSK US, Sangamo Therapeutics, Spark Therapeutics, and L7 Informatics highlight the complexity of the CGT supply chain, the risks involved and how building relationships is key to supply-chain development.
Fill out the form below to read the full eBook on supply chains now.
You May Also Like
